The effects of @entity3070 and moxidectin on egg viability and larval development of @entity3070 -resistant XXXX .

@entity3070 @entity5167 @entity742
The in vivo effects of @entity3070 and moxidectin on egg viability and larval development of @entity3070 -resistant @entity5167 were examined over time after anthelmintic treatment of @entity742 . Twenty merino @entity742 , (12 months old) were allocated to five treatment groups and infected with @entity3070 -resistant @entity5167 . Thirty one days later, the @entity742 were treated with intraruminal @entity3070 capsules, oral @entity3070 , oral moxidectin or injectable moxidectin at the manufacturer's recommended dosages, or left untreated. At various times up to 112 days after treatment, faecal egg counts (FEC) were determined and development rates of infective larvae (L3) cultured in faeces or on agar were measured. Eggs in faecal cultures from @entity3070 capsule treated @entity742 showed reduced L3 development percentages in comparison to faecal cultures from untreated @entity742 . Eggs from @entity3070 capsule treated @entity742 , isolated from faeces, and cultured on agar showed similar L3 development to eggs from control @entity742 . These results demonstrate an inhibitory effect of excreted @entity3070 in faeces on larval development of @entity3070 -resistant @entity5167 . L3 development in faecal culture from animals receiving oral @entity3070 were reduced for only 3 days after treatment. Faecal egg counts and development of L3 larvae in both culture systems from moxidectin treated @entity742 were low, due to the high efficacy of the drug. Egg counts in moxidectin treated @entity742 were reduced by approximately 90% 24h after treatment, before decreasing to almost 100% at 48h, suggesting that the current quarantine recommendation of holding @entity742 off pasture for 24h after treatment may still lead to some subsequent pasture contamination with worm eggs.
